1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)

EGTX.ST
Egetis Therapeutics AB (publ)SE flagStockholm Stock Exchange
5.88
SEK
+0.13
- -
2.22BMarket Cap

Total Valuation

Egetis Therapeutics AB (publ) carries a market capitalization of 2.22B, placing it among publicly traded companies globally. Its enterprise value stands at 2.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.22B
Enterprise Value2.00B

Share Statistics

Egetis Therapeutics AB (publ) currently has 395.16M shares outstanding.

Shares Outstanding395.16M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 32.82, and the price-to-book ratio stands at -1.03.

PE RatioN/A
PS Ratio32.82
PB Ratio-1.03
P/TBV Ratio-18.15
P/FCF Ratio-7.94
P/OCF Ratio-7.82

Enterprise Valuation

EV / Sales31.68
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Egetis Therapeutics AB (publ) maintains a current ratio of 0.69, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.28, indicating elevated leverage, while an interest coverage ratio of -20.39 demonstrates limited ability to service its debt obligations.

Current Ratio0.69
Quick Ratio0.60
Debt / Equity28.28
Debt / EBITDA-0.19
Interest Coverage-20.39

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-59.33
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover43.36

Taxes

Income Tax400,000.00
Effective Tax RateN/A

Stock Price Statistics

Egetis Therapeutics AB (publ)'s stock has gained approximately 24.84076% over the past 52 weeks. The 50-day moving average sits at 5.95, while the 200-day moving average is 5.45.

Beta (5Y)N/A
52-Week Price Change24.84076%
50-Day Moving Average5.95
200-Day Moving Average5.45
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Egetis Therapeutics AB (publ) generated 63.20M in revenue and converted that into -374.20M in net income, yielding earnings per share of -0.98. EBITDA reached -369.00M, while operating income came in at -369.00M.

Revenue63.20M
Gross Profit9.00M
Operating Income-369.00M
Pretax Income-373.80M
Net Income-374.20M
EBITDA-369.00M
EBIT-369.00M
Earnings Per Share (EPS)-0.98

Balance Sheet

Egetis Therapeutics AB (publ) holds 142.50M in cash and equivalents against 70.30M in total debt, resulting in a net debt position of -72.20M. Total book value stands at -2.02B, with working capital of -73.60M providing operational flexibility.

Cash & Cash Equivalents142.50M
Total Debt70.30M
Net Debt-72.20M
Equity (Book Value)-2.02B
Book Value Per Share-5.36
Working Capital-73.60M

Cash Flow

Egetis Therapeutics AB (publ) produced -265.30M in operating cash flow over the past twelve months. After subtracting -1.20M in capital expenditures, free cash flow totaled -266.50M - equivalent to -0.71 per share.

Operating Cash Flow-265.30M
Capital Expenditures-1.20M
Free Cash Flow-266.50M
FCF Per Share-0.71

Margins

Egetis Therapeutics AB (publ) operates with a gross margin of 14.24, reflecting its pricing power and cost economics. The operating margin of -583.86 and net profit margin of -592.09 provide insight into operational efficiency.

Gross Margin14.24
Operating Margin-583.86
Pretax Margin-591.46
Profit Margin-592.09
EBITDA Margin-583.86

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-6.72
FCF Yield-12.59

Stock Splits

Egetis Therapeutics AB (publ)'s most recent stock split took place on April 27, 2022 with a 1000:1089 split ratio.

Last Split Date4/27/2022
Split Ratio1000:1089

Scores

Egetis Therapeutics AB (publ) posts an Altman Z-Score of -19.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-19.20